The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin
- PMID: 14580034
- DOI: 10.1016/s1047-9651(03)00044-5
The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin
Abstract
Although much work is yet to be done in this area, nine general conclusions can be derived: 1. Local site-of-injection side effects from botulinum toxin injections are rare, assuming proper technique is used. 2. The two most common medication-related side effects from botulinum toxin orofacial injections are alterations in salivary consistency and inadvertent weakness of the swallowing, speech, and facial muscles. These complications are injection site-specific (eg, more common with lateral pterygoid injections and palatal and tongue muscle injections) and dose-dependent problems. These problems are bothersome but are not contraindications for the therapy if it is needed. 3. The data presented in this article are mostly case series-based and open trial-based information that is promising, but randomized, blinded, controlled trials are needed to establish the true efficacy of this method for the orofacial motor and pain disorders. 4. The novice should begin with injection of muscles he or she can inject with low risk of incorrect placement. The hard-to-find muscles should be avoided when starting out. The novice clinician should inject and dissect a few cadavers to improve injection technique. 5. The general latency for botulinum toxin type A is 1 week, its duration is 2 to 3 months, and it is recommended that injection be done no more than once every 12 weeks to avoid development of antibodies against the toxin. 6. Depending on the target muscle, injection dose is 10 to 50 U of Botox type A per site with a total dose of 200 U in the masticatory system. More than this can be used (400 U maximum) if other sites in the head and neck are included in the injection protocol. 7. Regarding injecting painful muscles that do not exhibit palpable muscle hardness or EMG-determined spasticity or observable involuntary movements but have chronic myofascial trigger points or the patient localizes them as the site of their chronic daily headache pain, botulinum toxin injections might be helpful used in this manner, but conclusive data for this controversial application of botulinum toxin are still missing. 8. Hemifacial spasm has the largest number of open-label, clinical trials, some of which have a 10-year follow-up. The conclusions reached by all of these reports is that treatment of hemifacial spasm with repeated injections of botulinum toxin has been highly successful and that the dose and relative effect of the injections are stable over time. 9. Although EMG-guided injection may be useful, EMG is neither practical nor needed in most situations for orofacial injections because most of the orofacial muscles are easily palpable muscles or have definitive bony landmarks to help with the localization process.
Similar articles
-
Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections.Ophthalmology. 1997 May;104(5):865-8. doi: 10.1016/s0161-6420(97)30220-6. Ophthalmology. 1997. PMID: 9160036 Clinical Trial.
-
Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects.Surv Ophthalmol. 1996 Jul-Aug;41(1):51-65. doi: 10.1016/s0039-6257(97)81995-9. Surv Ophthalmol. 1996. PMID: 8827930 Review.
-
[Hemifacial spasm treated with botulinum toxin].Rev Neurol (Paris). 1993;149(3):202-6. Rev Neurol (Paris). 1993. PMID: 8235213 French.
-
[The clinical usefulness of botulinum toxin type A for spasmodic torticollis and facial spasm].No To Shinkei. 1995 Aug;47(8):749-54. No To Shinkei. 1995. PMID: 7546919 Clinical Trial. Japanese.
-
Injectable neuromuscular blockade in the treatment of spasticity and movement disorders.J Child Neurol. 2003 Sep;18 Suppl 1:S50-66. doi: 10.1177/0883073803018001S0701. J Child Neurol. 2003. PMID: 13677571 Review.
Cited by
-
Change of distribution and timing of bite force after botulinum toxin type A injection evaluated by a computerized occlusion analysis system.Yonsei Med J. 2014 Jul;55(4):1123-9. doi: 10.3349/ymj.2014.55.4.1123. Yonsei Med J. 2014. PMID: 24954346 Free PMC article. Clinical Trial.
-
Review of the complications associated with treatment of oropharyngeal cancer: a guide for the dental practitioner.Quintessence Int. 2013 Mar;44(3):267-79. doi: 10.3290/j.qi.a29050. Quintessence Int. 2013. PMID: 23444208 Free PMC article. Review.
-
Botulinum toxin: The Midas touch.J Nat Sci Biol Med. 2014 Jan;5(1):8-14. doi: 10.4103/0976-9668.127274. J Nat Sci Biol Med. 2014. PMID: 24678189 Free PMC article. Review.
-
Bruxism and Botulinum Injection: Challenges and Insights.J Clin Med. 2023 Jul 10;12(14):4586. doi: 10.3390/jcm12144586. J Clin Med. 2023. PMID: 37510701 Free PMC article. Review.
-
Effects of botulinum toxin on jaw motor events during sleep in sleep bruxism patients: a polysomnographic evaluation.J Clin Sleep Med. 2014 Mar 15;10(3):291-8. doi: 10.5664/jcsm.3532. J Clin Sleep Med. 2014. PMID: 24634627 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources